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Abstract
Italy was the first Western country to face the COVID-19 pandemic. Here we report the results of a national survey on kidney 
transplantation activity in February and March 2020, and the results of a three-round Delphi consensus promoted by four 
scientific societies: the Italian Society of Organ Transplantation, the Italian Society of Nephrology, the Italian Society of 
Anesthesia and Intensive Care, and the Italian Group on Antimicrobial Stewardship. All 41 Italian transplant centers were 
invited to express their opinion in the Delphi rounds along with a group of seven experts. The survey revealed that, starting 
from March 2020, there was a decline in kidney transplantation activity in Italy, especially for living-related transplants. 
Overall, 60 recipients tested positive for SARS-CoV2 infection, 57 required hospitalization, 17 were admitted to the ICU, and 
11 died. The online consensus had high response rates at each round (95.8%, 95.8%, and 89.5%, respectively). Eventually, 27 
of 31 proposed statements were approved (87.1%), 12 at the first or second round (38.7%), and 3 at the third (9.7%). Based 
on the Italian experience, we discuss the reasons for the changes in kidney transplantation activity during the COVID-19 
pandemic in Western countries. We also provide working recommendations for the organization and management of kidney 
transplantation under these conditions.
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Introduction
SARS-CoV2 is a positive-sense RNA virus belonging to 
the family of coronaviruses. It causes a flu-like syndrome 
of varying severity, that is potentially deadly. This disease 
is characterized by one or more of the following symptoms: 
fever, cough, myalgia, asthenia, dyspnea, sore throat, and 
diarrhea [1]. The virus was first identified in December 
2019 in Wuhan (China). As at April 13, 2020, there were 
1,773,084 cases of confirmed SARS-CoV2 infection world-
wide, and 111,652 deaths [2]. In Italy SARS-CoV2 infec-
tion was first diagnosed in Rome on January 30, 2020 in 
two Chinese tourists. The first death caused by the related 
disease, COVID-19, occurred on February 22, 2020, and 
involved a 78-year-old man [3]. As at April 13, 2020, SARS-
CoV2 infection was confirmed in 159,516 patients in Italy, 
with 20,465 deaths [4].
COVID-19 spreads primarily through contact with res-
piratory droplets of people  infected. In the majority of 
cases, it only causes mild symptoms and requires no medical 
intervention [1]. At least 20% of patients develop a massive 
and dysregulated inflammatory response, however, which 
leads to a “capillary leak syndrome” and acute respiratory 
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distress syndrome (ARDS). These patients may need ven-
tilatory support and hospitalization in intensive care units 
(ICUs) [5, 6]. Other complications include shock, acute 
heart dysfunction, and acute kidney failure. The overall 
COVID-19 mortality rate is in the range of 3.7–11% [1].
Reliable information on the rate of SARS-CoV2 infection 
in uremic patients, be they transplanted [7] or on chronic 
dialysis [8], are not yet available, but immunosuppression 
is expected to increase the risk and severity of the infection 
in kidney transplant recipients.
Italy has universal health coverage insured by a national 
health system. After the outbreak of COVID-19 in north-
ern parts of the country, the Italian government promptly 
issued social distancing measures, quickly introducing a 
country-wide lockdown, and the national health system 
adopted specific strategies to deal with the epidemic, while 
protecting both patients and health care personnel. The 
Civil Protection Department coordinated all these actions 
[4]. Clinical workflow was revolutionized to prioritize 
resources for the care of COVID-19 patients, while main-
taining acceptable levels of activity for urgent procedures 
for the general population. Meanwhile, the Italian Trans-
plant Agency (CNT) released recommendations on how to 
manage transplant programs [9]. As the pandemic spread 
in other Western countries, their regulatory transplant agen-
cies issued other documents [10].
Despite the tremendous efforts made in the last 2 months 
to cope with the viral infection worldwide, there is still no 
objective evidence of the impact of the COVID-19 pandemic 
on kidney transplantation activities and, more importantly, 
there is still no guidance on clinical decisions. The aim of 
this survey and on-line consensus was specifically to provide 
this missing information.
Methods
Organizing committee
The survey and consensus were organized by the joint com-
mittee of the Italian Society of Nephrology and the Italian 
Society of Organ Transplantation.
Participants
In Italy, kidney transplantation programs (n = 41) are part of 
the public health system, and all the centers involved were 
invited to participate in this survey. For the consensus, seven 
experts were also invited to take part in the Delphi rounds. 
This group of experts consisted of former heads of some 
of the largest transplant centers in Italy (Enzo Capocasale, 
Claudio Ponticelli, Silvio Sandrini, Francesco Paolo Schena, 
Giuseppe Segoloni), a  representative of the territorial 
nephrologists in charge of long-term follow-up (Decenzio 
Bonucchi), and an expert on Infectious Diseases at the Ital-
ian Transplant Agency (Paolo Grossi)”.
Discussants
Consensus results were discussed by experts from the Italian 
Society of Anesthesia and Intensive Care, and the Italian 
Group on Antimicrobial Stewardship. The Director of Italian 
Transplant Agency (CNT), and specialists in Legal Medicine 
were also asked to discuss the document.
Number of kidney transplants
Transplant centers were asked to provide figures on kid-
ney transplants performed in the month of February, and 
between March 1st and March 15th, for the years 2018, 
2019, and 2020.
Survey
An 11-item survey enquired about the practice of kidney 
transplantation in Italy between equivalent periods of time in 
2019 and 2020 (January 1st–March 15th). It was prepared by 
the joint committee of the Italian Society of Transplantation 
and Italian Society of Nephrology, and covered the issues 
raised during remote focus groups held from March 9 to 
March 11th. The questionnaire also included a space for free 
comments (Table 1). The survey thus contained physicians’ 
opinions and aggregate data on patients at each transplant 
center.
Consensus
The organizing committee identified seven main domains of 
interest, and defined 31 critical items to address (Tables 2, 
3). A three-round Delphi consensus [11, 12] was then con-
ducted using an online platform made secure by using an 
academic account (https ://docs.googl e.com/forms ). Consen-
sus was defined as at least an 80% level of agreement. Items 
not reaching consensus were modified in the light of com-
ments from respondents, then sent back for the next round. 
Results
Survey
The survey had a 95.1% response rate (Table 1).
Between February 1, and March 15, 2020, a total of 261 
kidney transplants were performed. As shown in Fig. 1, there 
was no reduction in transplantation activity in the month of 
February compared with the years 2018 and 2019. In the 
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first two weeks of March, 2020, however, there was a clear 
decline in kidney transplantation activity, especially for liv-
ing-related procedures (Fig. 1). These figures are reflected 
in the statements (Table 1). Although more than 70% of 
the centers reported having been fully operational for trans-
plantations from deceased donors, several centers admitted 
having become more selective in accepting donors for kid-
ney transplantation. Modifications to their selection crite-
ria also included a preference for transplantations involv-
ing local recipients, though a statement specifically asking 
about the systematic implementation of this policy was not 
approved in the Delphi rounds (Table 3).
Only three centers reported having suspended their kid-
ney transplantation program. These programs were hosted in 
cities in northern Italy, where the incidence of SARS-CoV2 
infection was extremely high. Eight other centers only per-
formed transplantation procedures in urgent cases.
Outpatient follow-up activities were reduced at most 
centers (89.8%). In-person visits were warranted only for 
patients transplanted < 3–6 months previously, and for medi-
cal emergencies. The use of telemedicine was preferred for 
all other transplant recipients.
Most programs either suspended  (n = 18; 46.2%) or 
limited (n = 14; 35.8%) visits for the enrolment of patients 
on the waiting list for a transplant.
Sixty recipients tested positive for SARS-CoV2 infection, 
including three who were transplanted in February–March, 
2020. Fifty-seven recipients (95.0%) required hospitalization, 
including 17 who necessitated intensive care (28.3%), and 11 
who died (18.3%).
Eighteen transplant professionals (9 physicians and 9 
nurses) became infected with SARS-CoV2.
Finally, before the Italian Transplant Agency (CNT) made 
pre-transplant nasopharyngeal swabs (NPhS) mandatory, 26 
of 39 centers had already adopted this practice.
Consensus
The overall response rate was 95.8% at both the first and the 
second Delphi round, and 89.5% at the third.
Out of 31 proposed statements, there was a consensus 
for 27. Twelve items were agreed at the first or second round 
(38.7%), and 3 at the third (9.7%) (Table 2). Four items were 
filed without a consensus (12.9%) (Table 3). The consensus 
was formally divided into seven sets of statements (S).
Table 1  Italian survey on practice of kidney transplantation during COVID-19 outbreak
a Response from all the 34 centers with an active live donor program for kidney transplantation
b Response from 39 out 41 (95.1%) kidney transplant centers
c Response from 36 out 41 (87.8%) kidney transplant centers
1. Between February 17, 2020 and March 15, 2020, living-related kidney transplantation 
 wasa:
STOPPED
n (%)
19 (55.9%)
REDUCED
n (%)
10 (29.4%)
FULLY ACTIVE
n (%)
5 (14.7%)
2. Between February 17, 2020 and March 15, 2020, deceased donor kidney transplantation 
 wasb:
STOPPED
n (%)
3 (7.7%)
REDUCED
n (%)
8 (20.5%)
FULLY ACTIVE
n (%)
28 (71.8%)
3. Between February 17, 2020 and March 15, 2020, outpatient follow-up activity  wasb: STOPPED
n (%)
2 (5.1%)
REDUCED
n (%)
35 (89.8%)
FULLY ACTIVE
n (%)
2 (5.1%)
4. Between February 17, 2020 and March 15, 2020, enrollment on transplant waiting list 
 wasb:
STOPPED
n (%)
18 (46.2%)
REDUCED
n (%)
14 (35.8%)
FULLY ACTIVE
n (%)
7 (17.9%)
5. As of March 17, 2020, how many kidney transplant recipients tested positive for COVID-
19?b
60
6. How many COVID-19 positive recipients were transplanted in the year 2020? 3 (5.0%)
7. As of March 17, 2020, how many COVID-19 positive recipients required hospitalization?b 57 (95.0%)
8. As of March 17, 2020, how many COVID-19 positive recipients required Intensive Care 
Unit treatment?b
17 (28.3%)
9. As of March 17, 2020, how many COVID-19 positive recipients have died?b 11 (18.3%)
10. As of March 17, 2020, have you recorded cases of COVID-19 positivity in staff members 
caring for transplant recipients?b
PHYSICIANS
9
NURSES
9
11. Do you screen recipients before transplantation for occult SARS-CoV2 infection? YES
n (%)
26 (72.2%)
NO
n (%)
10 (27.8%)
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Table 2  Agreed statements for kidney transplant practice during COVID-19 pandemic
Domain Statement Agreement (%) Round
1. Kidney transplantation S1.1 During COVID-19 pandemic, live donor transplantation should 
be delayed, unless urgent conditions apply
98 1
S1.2 During COVID-19 pandemic, deceased donor renal transplanta-
tion should be performed only if COVID-19 free pathways can be 
ensured
96 2
S1.3 During COVID-19 pandemic, renal transplantation should 
be ensured to immunized patients and to recipients facing urgent 
clinical conditions. Individualized decisions should be taken for the 
remaining patients
83 2
2. Screening for occult COVID-19 infection S2.1 During COVID-19 pandemic, asymptomatic patients should 
be screened by nasopharyngeal swabs before proceeding to renal 
transplantation
94 1
S2.2 During COVID-19 pandemic, asymptomatic patients with 
acute rejection should be screened by nasopharyngeal swabs before 
administration of anti-rejection treatments
83 1
3. Immunosuppressive therapy S3.1 During COVID-19 pandemic, immunosuppression should be 
reduced in asymptomatic patients if nasopharyngeal swab is positive
87 1
S3.2 During COVID-19 pandemic, immunosuppression should be 
reduced in symptomatic patients with positive nasopharyngeal 
swabs without clinical or radiologic evidence of lung disease
96 1
S3.3 During COVID-19 pandemic, immunosuppression should be 
reduced in symptomatic patients with positive nasopharyngeal 
swabs with clinical or radiologic evidence of lung disease
94 1
S3.4 During COVID-19 pandemic, in patients with positive naso-
pharyngeal swabs reduction of immunosuppression should be 
gauged as follows:
  asymptomatic patients: withdraw of anti-proliferative agents;
 symptomatic patients without clinical or radiologic evidence of lung 
disease: withdraw of anti-proliferative agents and m-TOR inhibitors. 
Reduction in the dose of calcineurin inhibitors
 symptomatic patients with clinical or radiologic evidence of lung 
disease: withdraw of anti-proliferative agents, m-TOR inhibitors, 
and calcineurin inhibitors
87 2
S3.5 During COVID-19 pandemic, in transplant recipients recovering 
from COVID-19, infection immunosuppression should be re-intro-
duced 7–15 days after regression of symptoms, if nasopharyngeal 
swab is negative and after consultation with a specialist in Infectious 
Diseases
85 2
S3.6 During COVID-19 pandemic, levels of immunosuppression 
should be adjusted in patients who receive concurrent antiviral 
therapies, after consultation with a specialist in Infectious Diseases 
according to possible drug interactions
93 1
4. Other pharmacological agents S4.1 The use of Tocilizumab can be considered in kidney transplant 
recipients with severe pneumonia caused by SARS-CoV2 infection
98 1
S4.2 Steroid boluses can be used in renal transplant recipients with 
severe pneumonia caused by SARS-CoV2 infection who need inten-
sive care assistance
91 3
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Table 2  (continued)
Domain Statement Agreement (%) Round
5. Management of kidney transplant recipients S5.1 During COVID-19 pandemic, enrollment of patients in the wait 
list, for transplants from either deceased or live donors, could be 
delayed especially if the transplant center is located in an area with 
high prevalence of infection
95 3
S5.2 During COVID-19 pandemic, kidney transplant recipients and 
their cohabitants should strictly adhere to basic protective measures 
against virus diffusion
100 2
S5.3 During COVID-19 pandemic, active transplant programs must 
offer follow-up visits for patients in the early post-transplant period 
(3–6 months)
91 2
S5.4 During COVID-19 pandemic, kidney transplant outpatients with 
flu-like symptoms, without dyspnea, should be managed through 
COVID-19 positive pathways, established for the general popula-
tion. If hospitalization can be avoided, these recipients should be 
further assessed remotely. Reduction of immunosuppression could 
be advised
91 3
6. Healthcare professionals S6.1 During COVID-19 pandemic, cooperative remote recipient 
surveillance programs should be established by central transplant 
agencies, to offer post-transplant care to recipients from centers 
that have become inactive for outpatient services due to logistic or 
organizational constraints
89 1
S6.2 During COVID-19 pandemic, remote expert consultation 
programs should be established by central transplant agencies, to 
assist single centers in difficult management decisions for outpatient 
recipients
91 1
S6.3 During COVID-19 pandemic, post-transplant outpatient clin-
ics, in addition to the general safety measures, should include a 
dedicated space to manage patients with suspected viral infection. 
Standard safety procedures include surface disinfection after each 
visit
83 2
S6.4 During COVID-19 pandemic, healthcare professionals working 
in post-transplant outpatient clinics should wear first level personal 
protection equipment (surgical facemask, disposable isolation 
gowns and gloves)
96 2
S6.5 During COVID-19 pandemic, asymptomatic transplant profes-
sionals with positive nasopharyngeal swabs, must be placed on 
quarantine
91 1
S6.6 During COVID-19 pandemic, healthcare professionals taking 
care of kidney transplant recipients, once positive for COVID-19 
on nasopharyngeal swab, should stop their clinical activities and be 
isolated
93 2
7. Assessment of donor S7.1 During COVID-19 pandemic, live donors who have overcome 
SARS-CoV2 infection, with a currently negative nasopharyngeal 
swab, can be considered for donation only after a follow-up period 
of at least 3 months. In general, live donor renal transplantation 
should be delayed until the end of the pandemic, unless urgent 
conditions apply
93 2
S7.2 During COVID-19 pandemic, nasopharyngeal swabs should be 
obtained from all deceased donors
89 1
S7.3 During COVID-19 pandemic, nasopharyngeal swabs should be 
obtained from all live donors in the 24 h before donation
87 1
S7.4 During COVID-19 pandemic, considering that nasopharyngeal 
swabs may be falsely negative, deep airway swabs should also be 
obtained from deceased donors
89 2
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GROUP 1: Kidney transplant activity
S.1.1 During the COVID-19 pandemic, live donor trans-
plantation should be delayed unless urgent conditions apply. 
(Agreement rate 98%; Delphi round 1).
Comments Urgent conditions only relate to lack of vas-
cular accesses for dialysis and/or unfeasibility of perform-
ing  peritoneal dialysis. Semi-urgent conditions, such as 
preemptive recipients wishing to avoid dialysis, are  not 
included in this category because there is  no perceived 
advantage compared with  the potential risk of SARS-
CoV2 infection.
S.1.2 During the COVID-19 pandemic, deceased donor 
kidney transplantation should be performed only if COVID-
19 free pathways can be ensured. (Agreement rate 96%; Del-
phi round 2).
Comments Besides  the availability of COVID-19-free 
pathways, respondents outlined the importance of the timely 
Table 3  Statements not reaching consensus
Main topic Statement % Agreement
Round 1
n = 46 (%)
Round 2
n = 46 (%)
Round 3
n = 43 (%)
Kidney transplant activity During COVID-19 pandemic, local graft allocation should be preferred to 
reduce patient migration from areas of low-incidence to areas of high-
incidence of infection
59 65 77
During COVID-19 pandemic, graft shipping from areas of high-incidence 
to areas of low-incidence of infection should be preferred to patient 
migration from areas of low-incidence to areas of high-incidence of infec-
tion
59 65 58
Other pharmacological agents Asymptomatic patients with positive nasopharyngeal swabs should receive 
antibiotic prophylaxis
22 25 23
Modification of ACE-inhibitors based anti-hypertensive therapy should 
be considered in symptomatic kidney transplant recipients with positive 
nasopharyngeal swabs
41 63 56
Fig. 1  Number of kidney transplants performed in Italy in the month of February and the first 15 days of March, in three consecutive years 
(2018–2020). Black bars are living-donor (LD) kidney transplants. Grey bars are deceased-donor (DD) kidney transplants
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availability of nasopharyngeal swab, intensive care services, 
and specifically-trained personnel.
S1.3 During the COVID-19 pandemic, kidney transplan-
tation should be assured for immunized patients and recipi-
ents in urgent clinical conditions. Individualized decisions 
should be taken for other patients. (Agreement rate 83%; 
Delphi round 2).
Comments Transplantation  should be deemed life-saving 
for recipients who cannot be maintained on chronic dialysis, 
and should be delivered accordingly. Transplantation should 
also be assured for hyperimmunized patients due to the lim-
ited chances of finding a compatible donor.
GROUP 2: Nasopharyngeal swabs for COVID
S2.1 During the  COVID-19 pandemic, asymptomatic 
patients should be screened using nasopharyngeal swabs 
before proceeding to kidney transplantation. (Agreement 
rate 94%; Delphi round 1).
Comments Nasopharyngeal swab detects SARS-CoV2 by 
means of a  reverse-transcriptase–polymerase-chain-reac-
tion (RT-PCR) assay. The method is widely used to screen 
asymptomatic patients [13]. Its reliability in screening pro-
grams is questionable, however, because studies supporting 
it  are retrospective and refer to  patients hospitalized with 
pneumonia. Nasopharyngeal swab may miss recent SARS-
CoV2 infections [14]. In a population at low risk of infec-
tion, nasopharyngeal swabs  have a good specificity and a 
high negative predictive value (approaching 100%). In 
Italy, the Italian Transplant Agency (CNT) mandated naso-
pharyngeal swab in all transplant recipients. A good degree 
of coordination is needed to ensure that the results of naso-
pharyngeal swab become available in time.
S2.2 During the COVID-19 pandemic, asymptomatic 
patients with acute rejection should be screened with naso-
pharyngeal swabs before any anti-rejection treatments are 
administered. (Agreement rate 83%; Delphi round 1).
Comments Infection should be ruled out  especially in 
asymptomatic patients requiring anti-T-cell therapies and/or 
other vigorous boosts of immunosuppression.
GROUP 3: Immunosuppressive therapy
S3.1 During the COVID-19 pandemic, immunosuppression 
should be reduced in asymptomatic patients testing posi-
tive on a nasopharyngeal swab. (Agreement rate 87%; Del-
phi round 1).
S3.2 During the  COVID-19 pandemic, immunosup-
pression should be reduced in symptomatic patients test-
ing positive on a nasopharyngeal swab but with no clinical 
or radiological evidence of lung disease. (Agreement rate 
96%; Delphi round 1).
S3.3 During the COVID-19 pandemic, immunosuppres-
sion should be reduced in symptomatic patients testing posi-
tive on a nasopharyngeal swab and with clinical or radiologi-
cal evidence of lung disease. (Agreement rate 94%; Delphi 
round 1).
S3.4 During the COVID-19 pandemic, the reduction of 
immunosuppression for patients testing positive on a naso-
pharyngeal swab should be gauged as follows:
• asymptomatic patients: withdrawal of anti-proliferative 
agents
• symptomatic patients with no clinical or radiological evi-
dence of lung disease: withdrawal of anti-proliferative 
agents and m-TOR inhibitors; reduced dosage of cal-
cineurin inhibitors;
• symptomatic patients with clinical or radiological evi-
dence of lung disease: withdrawal of anti-proliferative 
agents, m-TOR inhibitors, and calcineurin inhibitors. 
(Agreement rate 87%; Delphi round 2)
Comments (S3.1–4) Immunological response to infec-
tion is reduced in almost all kidney transplant recipients 
due to long-term administration of  immunosuppressants 
[15, 16]. Immunosuppression may also significantly influ-
ence the clinical presentation and course of viral infections 
[17, 18], that tipically take a severe course  in immuno-
compromised hosts [19]. This would suggest the need to 
reduce  immunosuppression in kidney transplant recipients 
with SARS-CoV2 infection.
Although a personalized approach is warranted, this 
consensus provides general recommendations for manag-
ing immunosuppression based on severity of SARS-CoV2 
infection. Azathioprine and mycophenolic acid/mycophe-
nolate mofetil should be discontinued first because they 
preferentially inhibit T cell function and increase suscep-
tibility to viral infections [20]. Although mTOR inhibitors, 
have some anti-viral effects [21], they should be discontin-
ued next as they can cause various types of lung disease [22] 
that might complicate the interpretation of radiological and 
clinical findings in patients at risk of viral pneumonia. While 
a minimization/discontinuation of calcineurin inhibitors has 
been associated with an improved course of several viral 
infections (including CMV, BKV, HHV8 and EBV) [15], 
these drugs have also been shown to inhibit the proliferation 
of several coronaviruses in vitro [23–25], so they should be 
discontinued last.
Low-dose oral corticosteroids, used for maintenance 
should not be discontinued in order  to reduce the risk 
of acute rejection while preventing the onset of adrenal 
insufficiency. Steroids may also have a role in controlling 
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the dysregulated innate immune response of COVID-19 
pneumonia.
S3.5. During the COVID-19 pandemic,  immunosup-
pression should be restored 7–15 days after symptoms have 
regressed in transplant recipients recovering from SARS-
CoV2 infection, providing their nasopharyngeal swabs are 
negative and subject to consultation with an infectious dis-
eases specialist (Agreement rate 85%; Delphi round 2).
Comments No clear data exist to suggest  the best  timing 
for restoring  full immunosuppression after recovery from 
SARS-CoV2 infection. The threshold given here was estab-
lished  arbitrarily after discussions within the organizing 
committee and an analysis of comments arriving after the 
first Delphi round.
S3.6. During the COVID-19 pandemic, immunosuppres-
sion levels should be adjusted in patients given concurrent 
antiviral therapies, after consultation with an infectious dis-
eases specialist regarding possible drug interactions. (Agree-
ment rate 93%; Delphi round 1).
Comments Antiviral agents are known to interact with 
immunosuppressants  [26, 27]. Levels of immunosuppres-
sion should be tailored accordingly.
GROUP 4: Other pharmacological agents
S4.1. The use of tocilizumab can be considered in kidney 
transplant recipients with severe pneumonia caused by 
SARS-CoV2 infection. (Agreement rate 98%; Delphi round 
1).
Comments Tocilizumab is a humanized monoclonal anti-
body against interleukin-6 receptor (IL-6R), commonly used 
for rheumatoid arthritis. Tocilizumab has been employed 
off-label in the treatment of antibody-mediated rejection 
and, based on recent clinical trials, it appears to be safe in 
this clinical setting [28, 29].
The rationale for using tocilizumab in SARS-CoV2 
infection is the clinical relevance of the related inflamma-
tory reaction caused by an enhanced release of IL-6, IL-10, 
and TNF-alpha. This so-called cytokine storm (recently 
described in patients, in Wuhan) is also characterized by 
other immunological dysfunctions, such as a decrease 
in CD4+ T and CD8+ cell counts, and IFN-γ production 
[30]. Blockade of the IL-6/IL-6R pathway may limit lung 
injury and the triggering of systemic inflammation that can 
lead to multiple organ failure, including acute kidney graft 
dysfunction.
An ongoing multicenter, single-arm, open-label, phase 2 
study (TOCIVID-19) (NCT04317092) is investigating the 
efficacy of tocilizumab in patients with COVID-19 pneu-
monia (8 mg/kg every 12 h, with a maximum of 800 mg per 
dose) [31]. Transplant recipients cannot be enrolled in this 
study, however, because previous immunosuppression is one 
of the exclusion criteria.
S4.2. Steroid boluses can be used in kidney transplant 
recipients with severe pneumonia caused by SARS-CoV2 
infection in need of intensive care. (Agreement rate 91%; 
Delphi round 3).
Comments Despite conflicting evidence [32], steroids 
could be beneficial in treating the hyperinflammation asso-
ciated with COVID-19 pneumonia [33]. The decision to use 
steroids should be shared with the intensive care providers 
responsible for these critically-ill patients because timing 
[34] and dosage [35] of  the treatment are important fac-
tors to maximize patients’ chances of survival. In transplant 
recipients the use of steroids is further justified by the con-
current need to reduce/withdraw chronic immunosuppres-
sion. Another consideration in favor of using steroids is that 
the SARS-CoV2  infection of lung alveolar epithelial and 
endothelial cells has been shown to induce a maladaptive 
repair mechanism  leading to fibrosis [36]. In this setting, 
steroids may limit the virus’s profibrotic activity and contain 
lung dysfunction. Steroids are mandatory if tocilizumab is 
used [37].
Guidelines from the Society of Critical Care Medicine 
and the European Society of Intensive Care Medicine recom-
mend iv. methylprednisolone 1 mg/kg/day in patients with 
moderate-to-severe forms of ARDS  (PaO2/FiO2 < 200). In a 
recent multicenter trial, early administration of dexametha-
sone (20 mg once daily on days 1 to 5, then 10 mg once daily 
on days 6 to 10) to 277 patients with established moderate-
to-severe ARDS reduced the duration of their mechanical 
ventilation and overall mortality [38]. Finally, the Surviv-
ing Sepsis Campaign guidelines for treating critically-ill 
adults with COVID-19 recommend using steroids in ARDS 
patients [39].
GROUP 5: Management of kidney transplant recipients
S5.1. During the COVID-19 pandemic, the enrollment of 
patients on the waiting list for transplants from deceased 
or living donors could be delayed, especially if the trans-
plant center is in an area with a high prevalence of infection. 
(Agreement rate 95%; Delphi round 3).
S5.2. During the COVID-19 pandemic, kidney trans-
plant recipients and members of  their household should 
adhere strictly to basic measures to prevent the virus’s dif-
fusion. (Agreement rate 100%; Delphi round 2).
S5.3. During the COVID-19 pandemic, active transplant 
programs should offer follow-up visits for patients in the 
early post-transplant period (3–6 months). (Agreement rate 
91%; Delphi round 2).
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S5.4. During the COVID-19 pandemic, kidney transplant 
outpatients with flu-like symptoms, but no dyspnea, should 
be managed through pathways established for COVID-
19-positive cases in the general population. If hospitalization 
can be avoided, these kidney transplant recipients should 
continue to be assessed remotely. A reduction of their immu-
nosuppression could be recommended. (Agreement rate 
91%; Delphi round 3).
Comments (S5.1–4) This set  of statements indicates that 
preventive and protective measures applied to the general 
population should be strictly adopted also by transplant 
recipients. Transplant centers should also be able to assure 
patient  follow-up soon after transplantation (3–6 months). 
If working conditions prevent this from taking the form of 
in-person visits, then remote follow-up should be offered.
GROUP 6: Healthcare professionals
S6.1 During the COVID-19 pandemic, cooperative remote 
recipient surveillance programs should be established by 
central transplant agencies, to offer post-transplant care to 
recipients from centers that have become inactive for out-
patient services due to logistic or organizational constraints. 
(Agreement rate 89%; Delphi round 1).
S6.2. During the COVID-19 pandemic, remote expert 
consultation programs should be established by central 
transplant agencies, to assist single centers in difficult man-
agement decisions for outpatient recipients. (Agreement rate 
91%; Delphi round 1).
S6.3. During the COVID-19 pandemic, post-transplant 
outpatient clinics, in addition to the general safety meas-
ures, should allocate a dedicated space for managing patients 
with a suspected viral infection. Standard safety procedures 
include surface disinfection after each visit. (Agreement rate 
83%; Delphi round 2).
S6.4. During the COVID-19 pandemic, healthcare profes-
sionals working in post-transplant outpatient clinics should 
wear first-level personal protective equipment (surgical face 
masks, disposable isolation gowns and gloves). (Agreement 
rate 96%; Delphi round 2).
S6.5. During the COVID-19 pandemic, asymptomatic 
transplant professionals testing positive on nasopharyngeal 
swab must be quarantined. (Agreement rate 91%; Delphi 
round 1).
S6.6. During the COVID-19 pandemic, health care pro-
fessionals taking care of kidney transplant recipients who 
test  positive for COVID-19 on nasopharyngeal swab, 
should  suspend their clinical activities and be isolated. 
(Agreement rate 93%; Delphi round 2).
Comments (S6.1–6) In times when  resources have to be 
prioritized, as in this  COVID-19 pandemic, most hospi-
tals have retained  the ability to cope with  urgent surgery. 
Organ transplantation  is, by definition, an urgent proce-
dure. Other activities, such as outpatient services, were sus-
pended or drastically reduced because they were considered 
non-essential and to contain hospital congestion. Reducing 
the latter  services was also thought to make extra  human 
resources free for the care of acutely ill patients [40]. That 
said,  even if transplantation activities had  stopped, trans-
plant services are still taking care of many patients in fol-
low-up. Transplant outpatient services should therefore be 
maintained during COVID-19 pandemic, taking steps to 
ensure the safety of both health care providers and recipi-
ents. Statement S6.1–6 addresses these new and very com-
plex issues. New organizational models are needed, such as 
inter-institutional cooperation  schemes and/or the creation 
of centralized services for teleconsultation.
As for protecting health care professionals [41], and pre-
venting the nosocomial diffusion of the disease [42], the 
statements herein are consistent with the general recom-
mendations of the Center for Disease Control and Preven-
tion [43].
GROUP 7: Donor assessments
S7.1. During the COVID-19 pandemic, living donors who 
have overcome SARS-CoV2 infection, with a currently neg-
ative nasopharyngeal swab, can be considered for donation 
only after a follow-up period of at least 3 months. In general, 
living donor kidney transplantation should be delayed until 
the end of the pandemic, unless urgent conditions apply. 
(Agreement rate: 93%. Delphi round 2).
Comments Needless to say, the safety of living donors is of 
the utmost importance [44]. In most patients, SARS-CoV2 
is no longer detectable 10–20 days after its symptoms have 
disappeared [45, 46], and there have been  no reports  of 
direct COVID-19 transmission from donors to  transplant 
recipients, but the time it takes for definite viral clearance 
is still unknown. Bearing in mind that living  donor kid-
ney transplantation is an elective procedure, the consensus 
group agreed that extra safety measures should be adopted, 
waiting for at least 3 months after a negative nasopharyn-
geal swab.
S7.2. During the COVID-19 pandemic, nasopharyngeal 
swabs should be obtained from all deceased donors. (Agree-
ment rate: 89%. Delphi round 1).
Comments In Italy, the use of nasopharyngeal swab 
on  donors became mandatory soon after the outbreak of 
COVID-19. The Italian Transplant Agency (CNT) has 
recently also mandated bronchoalveolar lavage fluid analy-
sis. There is no clear evidence of COVID-19 being transmit-
ted via the blood or transplanted solid organs, but the lack 
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of effective antiviral strategies and the need for immunosup-
pression make it wise for donors to be screened for occult 
SARS-CoV2 infection. In donors with a recent computed 
tomography of the chest, their  radiological images could 
also be used to rule out SARS-CoV2 infection [47]. It  is 
worth adding that COVID-19 can cause direct kidney injury 
[48].
S7.3. During the COVID-19 pandemic, nasopharyngeal 
swabs should be obtained from all living donors in the 24 h 
before donation. (Agreement rate: 87%. Delphi round 1).
Comments Most hospitals have created COVID-19-free 
pathways. Transplant procedures should be managed in 
these pathways, making screening for occult SARS-CoV2 
infection prior to admission mandatory. Living donors must 
also follow this pathway.
S7.4. During the  COVID-19 pandemic, deep airway 
swabs should also be obtained from deceased donors because 
nasopharyngeal swabs may produce false negative results. 
(Agreement rate: 89%. Delphi round 2).
Comments The Italian Transplant Agency (CNT) and the 
Italian Transplantation Society recommend bronchoalveolar 
lavage fluid analysis in organ donors [49]. The rationale for 
this additional test is that COVID-19 causes a viral pneu-
monia so that the virus could be missed in upper airways 
while being present in the lower respiratory tract. In keeping 
with this theoretical background, bronchoalveolar lavage 
fluid analysis is also mandatory in Italy for patients requir-
ing mechanical ventilation before they can be admitted  to 
a COVID-19-free intensive care units. Although pre-opera-
tive bronchoalveolar lavage analysis is not feasible in trans-
plant recipients, swabs from deep airways could be obtained 
at the time of tracheal intubation. The results  will not be 
available until after the transplant but could still allow for 
“preemptive therapy”, if unexpectedly found positive.
Discussion
Our survey shows that as of March 1, 2020, when the inci-
dence of SARS-CoV2 infection started to rise steeply [4], 
in Italy kidney transplantation activity has declined, espe-
cially for living donor transplantation. Only three centers, 
all in areas where the incidence of SARS-CoV2 infection 
was extremely high, completely suspended their activi-
ties. Nonetheless, over 80% of the programs either 
reduced or stopped the procedures for enrolling patients 
on the waiting list, and 95% reduced or stopped outpatient 
follow-up visits. In short, despite individual and institu-
tional efforts to ensure the continuation of transplantation 
activities, the COVID-19 pandemic has clearly affected the 
practice in Italy. The findings of this survey are in keeping 
with the recommendations of the consensus. While liv-
ing donor kidney transplantation should be avoided dur-
ing the COVID-19 pandemic, transplant centers need to 
take additional, specific precautions to remain active.
The risk of infection is low for kidney donors admitted 
to dedicated no-COVID19 surgery units and pre-emptive 
living-donor kidney transplant candidates with good social 
support who live in areas with a low incidence of SARS-
CoV2 infection (e.g., in Central and Southern Italy and 
some other parts of Europe.
Although the ongoing struggle against the virus has not 
stopped kidney transplantation in Italy, it has limited the 
number of procedures and posed new challenges for the 
overall management of transplant programs. Our survey 
provides a picture of the Italian situation in mid-March. 
Epidemiological data show that the incidence of SARS-
CoV2 infection continued to rise in Italy to mid-April [4], 
possibly making the final scenario even worse than the 
one described here.
Our survey also showed that, as at March 17, 2020, 
60 kidney transplant recipients in Italy were positive for 
SARS-CoV2 infection. This figure refers to the known 
incidence of infection in the population of kidney trans-
plant recipients as a whole—which is difficult to quan-
tify, so it should not be used to estimate the incidence 
of SARS-CoV2 infection in newly transplanted patients. 
Although several patients may have been missed due to 
the short follow-up period, and the risk of exposure to 
COVID-19 gradually increased as the infection spread in 
Italy, we identified only three cases of infection among 261 
patients transplanted between February 1 and March 
15, 2020 (1.1%). It  is worth noting, however, that 95% 
of the total infected recipients required hospitalization, 
28% needed ICU support, and 18% died. These percent-
ages show that SARS-CoV2 infection in kidney transplant 
recipients is a matter of serious concern, and reinforce 
the need for the strict implementation of protective meas-
ures. Although scarce, preliminary information on the 
prevalence and outcomes of COVID-19 in this popula-
tion suggests that kidney-transplant recipients are not at 
higher risk of acquiring the viral infection. That said, those 
affected seem to be at particularly high risk of becoming 
critically ill with COVID-19 due to their chronic immuno-
suppression and concomitant health issues [50].
Several serological tests have been proposed for measur-
ing SARS-CoV2-specific antibody response and diagnosing 
past SARS-CoV2 infections (particularly in asymptomatic 
cases or patients testing negative on nasopharyngeal swab). 
Identifying the presence or absence of specific antibodies in 
kidney transplant recipients may be helpful when it comes to 
making certain important clinical decisions (e.g., timing and 
mode of treatment for episodes of acute rejection, evaluation 
of living donation).
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Measuring SARS-CoV2-specific IgG antibody titers 
can also be useful in epidemiological studies to help cli-
nicians schedule outpatient follow-up visits appropriately 
and/or to allow for a safe return of patients to work.
These observations, along with the need to adjust 
immunosuppression levels in infected recipients, pose new 
questions regarding how to keep kidney transplant recipi-
ents informed during the COVID-19 pandemic. Emerging 
reports concerning the need to minimize or discontinue 
immunosuppression in the majority of COVID-19-positive 
patients should be discussed by health care professionals 
and their patients. A law recently enacted in Italy (Law 
219/2017) [51] establishes that every patient has the right 
to discuss their values, goals and preferences regarding 
their health care with physicians, and to have the chance to 
make decisions about their treatment. The law emphasizes 
the care relationship and the patient’s freedom to decide. 
As patients have demanded a more participatory role in 
decisions regarding their health care, they should be fully 
informed about the nature of their disease, its likely out-
come, and the risks and benefits of any proposed treat-
ments, and all these issues should be carefully discussed. 
Since patients should consider the risks and benefits of any 
treatment before giving their consent, the risks associated 
with minimizing or discontinuing immunosuppressants—
potentially changing the fate of a functioning kidney trans-
plantation—should be clearly explained so that patients 
can make a well-informed decision. A COVID-19-tailored 
information process will make it easier for clinicians and 
patients to make shared decisions, further empowering 
caregivers and patients in relation to their own health care.
Given the risk of infection by SARS-CoV2, patients 
on ambulatory hemodialysis could benefit from a preemp-
tive kidney transplantation  providing the transplant 
surgery can be managed at COVID-19-free transplant 
centers, and only after testing donors and recipients for 
COVID-19  with nasopharyngeal swab. Patients  may 
also need to be hospitalized for longer than usual to pro-
tect them against the higher risk of SARS-CoV2 infection 
(associated mainly with the use of induction agents and 
high doses of immunosuppressants).
Our Delphi consensus produced 27 recommendations 
intended to provide guidance on  the practice of kidney 
transplantation during the COVID-19 pandemic. Questions 
could not be posed in the PICO format, and recommenda-
tions could not be graded [52], due to the lack of relevant lit-
erature to date. Rapidly-evolving research may generate this 
information soon, but the explosive nature of the COVID-19 
pandemic makes it necessary to have some guidelines now, 
even in the current form of an expert opinion.
In short, as already suggested by several reports [53, 54], 
the COVID-19 pandemic has major implications for kid-
ney transplantation activities, and of kidney transplant 
management programs. Several recommendations are pro-
vided here to help in this difficult process.
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